Osteosarcoma and other tumors of bone.
The report of results from a major randomized clinical trial of neoadjuvant chemotherapy for operable osteosarcoma and the experience of two groups with neoadjuvant chemotherapy for patients with malignant fibrous histiocytoma of bone mark the major clinical advances of the past year. Further work on prognostic factors, including p-glycoprotein, oncogenes, and genes related to cell cycle control, as well as promising novel therapeutics, appeared in the literature and will likely result in new areas of clinical investigation.
Mertens
W C
WC
Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State University, Harper Hospital, Detroit, MI 48201, USA.
Bramwell
V C
VC
D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D006801:Humans; D012516:Osteosarcoma / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011379:Prognosis